NFKB1 and plasma cell myeloma: Furthermore, it is known that tumor cells make use of the non-canonical pathway for NF-κB activation, because BC (MDA-MB-231) and myeloma (U266) cells have been shown to induce RANKL-mediated osteoclastogenesis in mouse macrophage (RAW264.7) cells together with increased expression and phosphorylation and degradation of the IkB and thus with the inhibition of NF-κB activation.